
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6). Please refer to the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 11/1/26**
(See policy history boxes for previous effective dates)

Title: Miscellaneous and Genetic and Molecular Diagnostic Tests

Description

There are numerous commercially available genetic and molecular, diagnostic and prognostic, tests for individuals with certain diseases. This evidence review evaluates miscellaneous genetic and molecular diagnostic tests (e.g., next-generation sequencing [NGS]) not addressed in a separate review and have not received clearance/approval/de novo classification from the Food and Drug Administration (FDA). If a separate evidence review exists, then conclusions reached there supersede conclusions here. The main criterion for inclusion in this review is the limited evidence on the clinical validity for the test. As a result, these tests do not have clinical utility, and the evidence is insufficient to determine that technology results in an improvement in the net health outcome.

TESTS ADDRESSED IN THIS EVIDENCE REVIEW

Table 1 lists genetic, molecular, and other laboratory diagnostic tests assessed in this evidence review. Diagnostic, prognostic, and future-risk applications are included depending on the intended use of the test.

Table 1. Genetic, Molecular Diagnostic, and Phenotypic Tests Assessed This Evidence Review

Test Name	Manufacturer	Date Added	Diagnostic	Prognostic	Future Risk
Prometheus® Celiac PLUS	Prometheus Laboratories	Oct 2014	•		•
Prometheus® Crohn's Prognostic	Prometheus Laboratories	Oct 2014		•	
DNA Methylation Pathway Profile	Great Plains Laboratory (now Mosaic Dxcs)	Jan 2015	•		
GI Effects® (Stool)	Genova Dxcs	Jan 2015	•		
Prometheus® IBD sgi Diagnostic™	Prometheus Laboratories	Oct 2014	•		

Know error®	Strand Dxcs	July 2016	•		
Carbapenemase enzyme activity testing phenotypic assays (e.g., modified carbapenem inactivation method [mCIM], Carba NP testing)	N/A	Jan 2026	•		
Carbapenemase resistance genes (e.g., KPC, NDM, VIM, IMP, OXA 48)	N/A	Jan 2026	•		
Envisia Genomic Classifier	Veracyte	Nov 2021	•		

Dxcs: Diagnostics.

^a No therapeutic tests have been identified for this policy.

Medical Policy Statement

Diagnostic and prognostic genetic testing of (1) an affected (symptomatic) individual's germline to benefit the individual (excluding reproductive testing) **or** (2) of an asymptomatic individual to determine future risk of disease is considered experimental/investigational for the following:

- Prometheus® Celiac PLUS
- Prometheus® Crohn's Prognostic
- DNA Methylation Pathway Profile
- GI Effects® (Stool)
- Prometheus® IBD sgi Diagnostic®
- Know Error®
- Envisia™ Genomic Classifier (Veracyte™)

The use of carbapenemases resistance-gene testing, and/or phenotypic carbapenemase enzyme activity testing (e.g., modified carbapenem inactivation method [mCIM], Carba NP testing), is experimental/investigational. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

The use of next-generation sequencing tests that analyze conserved ribosomal RNA gene targets (e.g., 16S bacterial and 18S fungal sequences) to detect and identify microbial pathogens and associated antimicrobial resistance markers are experimental/investigational. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

The use of next-generation sequencing based testing of plasma for the detection and identification of fungal and acid-fast bacterial DNA associated with suspected invasive infection is experimental/investigational. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

All miscellaneous laboratory diagnostic tests^a listed in this policy are experimental/investigational. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

^a *If a separate policy exists, then the criteria in that policy supersede the guidelines herein.*

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

81265	81266	81382	81479	81554	82397
82784	83520	84999	86021	86140	86255
87045	87046	87075	87102	87177	87182
87183	87209	87328	87329	87336	87798
88346	88350	0112U	0531U		

^a These codes are considered experimental/investigational when used to bill for the Know Error test.

Established codes may be considered investigational for the purpose of this policy

Notes:

- Code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at BCBSM or BCN to verify coverage.
 - Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.
-

Background

DIAGNOSTIC TESTS

Multiple Conditions

Single-nucleotide variants (SNVs) are the most common type of genetic variation, and each SNV represents a difference in a single nucleotide in the DNA sequence. Most commonly, SNVs are found in the DNA between genes and can act as biologic markers of genes and disease association. When SNVs occur within a gene or a gene regulatory region, they can play a more direct role in disease by affecting the gene's function. SNVs may predict an individual's response to certain drugs, susceptibility to environmental factors, and the risk of developing certain diseases.

DNA specimen provenance assays can be used to confirm that tissue specimens are correctly matched to the patient of origin. Specimen provenance errors may occur in up to 1% to 2% of

pathology tissue specimens (1) and have serious negative implications for patient care if the error is not corrected.(2) Analysis of DNA microsatellites from tissue specimens can be performed by analyzing long tandem repeats (LTR) and comparing the LTRs of the tissue specimen with LTRs from a patient sample.

Test Description: DNA Methylation Pathway Profile

The DNA Methylation Pathway Profile (Mosaic Diagnostics) analyzes SNVs associated with certain biochemical processes, including methionine metabolism, detoxification, hormone imbalances, and vitamin D function. Intended uses for the test include clarification of a diagnosis suggested by other testing and as an indication for supplements and diet modifications.

Test Description: Know Error DNA Specimen Provenance Assay

The Know Error system (Strand Diagnostics) compares the LTRs of tissue samples with LTRs from a buccal swab of the patient. The intended use of the test is to confirm tissue of origin and avoid specimen provenance errors due to switching of patient samples, mislabeling, or sample contamination.

Test Description: Idiopathic Pulmonary Fibrosis Diagnostic Test (Envisia™ - Veracyte™)

The Envisia Genomic Classifier is a commercially available genomic classifier developed for evaluation of interstitial lung disease. A transbronchial biopsy specimen is obtained for mRNA sequencing of 190 genes and is combined with a machine learning algorithm to identify usual interstitial pneumonia patterns which provides a probabilistic estimate of the likelihood of idiopathic pulmonary fibrosis (IPF). Envisia is intended to be used as a complement to high-resolution chest CT (HRCT) to differentiate IPF from other interstitial lung diseases in patients who do not have a definite usual interstitial pneumonia and are suspected of having idiopathic pulmonary fibrosis. The Envisia genomic classifier is intended to provide a categorical usual interstitial pneumonia or non-usual interstitial pneumonia result that along with clinical and radiographic information may guide treatment without the need for surgical lung biopsy.

Celiac Disease

Previously called sprue, celiac sprue, gluten-sensitive enteropathy, gluten intolerance, nontropical sprue, or idiopathic steatorrhea, celiac disease is an immune-based reaction to gluten (water insoluble proteins in wheat, barley, rye) that primarily affects the small intestine. Celiac disease occurs almost exclusively in individuals who carry at least 1 human leukocyte antigen DQ2 or DQ8 allele; the negative predictive value of having neither allele exceeds 98%.(3) Serum antibodies to tissue transglutaminase, endomysium, and deamidated gliadin peptide (DGP) support a diagnosis of celiac disease, but diagnostic confirmation requires duodenal biopsy taken when patients are on a gluten-containing diet.(4)

Test Description: Celiac PLUS

Celiac PLUS (Prometheus Laboratories) is a panel of 2 genetic and 5 serologic markers associated with celiac disease. Per the manufacturer, Celiac PLUS is a diagnostic test that also stratifies the future risk of celiac disease. Genetic markers (human leukocyte antigen DQ2 and DQ8) are considered predictive of the risk of developing celiac disease;(6) serologic markers (immunoglobulin A [IgA] anti-tissue transglutaminase antibody, IgA anti-endomysial antibodies, IgA anti-DGP antibodies, IgG anti-DGP, and total IgA) are considered diagnostic for celiac disease. Celiac PLUS is intended for patients at risk for disease (e.g., with an affected first-degree relative) or with symptoms suggestive of disease.

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder that affects 10% to 20% of the general population in the United States and worldwide. Symptoms include abdominal pain and/or bloating associated with disordered bowel habit (constipation, diarrhea, or both). Pathophysiology is poorly understood but may be related to chronic low-grade mucosal inflammation and disturbances in GI flora.(7) Recommended treatments include dietary restriction and pharmacologic symptom control.(8-10) As living microorganisms that promote health when administered to a host in therapeutic doses,(11) probiotics are being investigated as a treatment for IBS. Several systematic reviews of randomized controlled trials (RCTs) have found evidence to support efficacy,(7,12-15) but results from recent randomized controlled trials have been mixed.(16-21) This discrepancy may be due in part to the differential effects of different probiotic strains and doses.

Test Description: GI Effects Comprehensive Stool Profile

The GI Effects Comprehensive Stool Profile (Genova Diagnostics) is a multianalyte stool assay.(22) The test combines multiple laboratory methods and standard biochemical and culture methods to measure levels of other stool components (e.g., lipids, fecal occult blood) and potential pathogens (ova and parasites, opportunistic bacteria, yeast). The test is purported to optimize management of gut health and to differentiate IBS from inflammatory bowel disease (IBD).

Inflammatory Bowel Disease

IBD is an autoimmune condition characterized by inflammation of the bowel wall and has clinical symptoms of abdominal pain, diarrhea, and associated symptoms. Crohn disease (CD) and ulcerative colitis are the two main entities under the category of IBD. The diagnosis is typically made by endoscopy or colonoscopy with biopsy and histologic analysis. This requires a semi-invasive procedure; as a result, a blood test to diagnose IBD could avoid the need for the procedures.

Test Description: IBD sgi Diagnostic

IBD sgi Diagnostic (Prometheus Laboratories) is a panel of 17 serologic (n=8), genetic (n=4), and inflammatory biomarkers (n=5). A proprietary algorithm produces an IBD score; results are reported as consistent with IBD (consistent with ulcerative colitis, consistent with CD, or inconclusive for UC vs CD) or not consistent with IBD. The test is intended for use in patients with clinical suspicion of IBD.

THERAPEUTIC TESTS

Previously reviewed therapeutic tests are no longer commercially available; no commercially available therapeutic test is reviewed in this policy.

PROGNOSTIC TESTS

Crohn Disease

Recent studies have identified serologic (23) and genetic (24,25) correlates of aggressive CD that is characterized by fistula formation, fibrostenosis, and the need for surgical intervention. Prometheus has developed a blood test that aims to identify patients with CD who are likely to experience an aggressive disease course.

Test Description: Crohn's Prognostic

Crohn's Prognostic (Prometheus Laboratories) is a panel of 6 serologic (n=3) and genetic (n=3) biomarkers. Limited information about the test is available on the manufacturer's website.

TESTS FOR FUTURE RISK OF DISEASE

Previously reviewed tests for future risk of disease are no longer commercially available; no commercially available test for the future risk of disease is reviewed in this policy.

CARBAPENEM-RESISTANCE ORGANISMS

Carbapenem-resistant organisms are a family of germs that are difficult to treat because they are resistant to nearly all antibiotics, including the most potent antibiotics on the market. The most common types of bacteria that can become carbapenem-resistant are Enterobacterales, *Pseudomonas* and *Acinetobacter* species. Examples of genes that produce a carbapenemase enzyme include KPC, NDM, OXA-48, IMP, and VIM. Carbapenems have often been considered the last line of defense in treating multidrug-resistant bacterial infections. Carbapenemase genes are capable of traveling on mobile genetic elements (e.g., plasmids), making it easier for resistance to spread between organisms and among individuals, especially at healthcare facilities, placing immunocompromised people and medically vulnerable populations at the highest risk.

Testing for carbapenemase enzyme activity is performed using phenotypic assays that demonstrate the organism's ability to hydrolyze or inactivate a carbapenem antibiotic. Common methods include the modified carbapenem inactivation method (mCIM), in which a carbapenem disk is exposed to the test organism and subsequently assessed for residual antimicrobial activity against a susceptible indicator strain; loss of activity indicates carbapenemase production. The Carba NP test is another widely used phenotypic assay that detects carbapenem hydrolysis through a colorimetric change resulting from pH alterations generated during enzymatic breakdown of the antibiotic. Additional phenotypic approaches include carbapenem inactivation assays, inhibitor-based tests, and other biochemical methods designed to detect functional carbapenemase activity in cultured bacterial isolates. These methods evaluate the presence of active enzyme production and are commonly used in clinical microbiology laboratories to identify carbapenemase-producing organisms.

MISCELLANEOUS LABORATORY TESTING

This conceptual framework is to assist in the evaluation of the utility of miscellaneous laboratory testing. In providing a framework for evaluating miscellaneous laboratory tests, this review may not determine the clinical utility of laboratory testing for specific disorders. Rather, it is meant to provide guidelines that can be applied to a wide range of laboratory tests.

This conceptual framework applies only if there is not a separate policy (see Related Policies) that outlines specific criteria for laboratory testing. If a separate policy exists, then the criteria in that policy supersedes the guidelines herein.

NEXT-GENERATION SEQUENCING (NGS)

Next-generation sequencing (NGS) is a high-throughput molecular technology that enables the simultaneous sequencing of millions of DNA (or RNA) fragments allowing comprehensive,

unbiased analysis of all genetic material within a clinical specimen. In infectious diseases, NGS is proposed as a diagnostic tool to identify a broad range of pathogens—including bacteria, viruses, fungi, and parasites—from a single sample without requiring prior knowledge of the suspected organism, with particular utility in detecting rare, fastidious, or unculturable organisms and in identifying polymicrobial infections or antimicrobial resistance-genes (when performed as part of a broad sequencing platform and not targeted PCR/NAAT testing). These capabilities may improve diagnostic yield, especially in complex or culture-negative cases. However, significant limitations exist, including difficulty distinguishing true infection from colonization or contamination, variability in test performance and lack of standardization, complex data interpretation requiring specialized bioinformatics, higher cost and longer turnaround times compared to conventional methods, and limited evidence demonstrating that its use improves clinical outcomes. These assays may include proprietary laboratory analyses (PLA codes) and are often used to detect circulating microbial cell-free DNA in plasma or other specimens. While NGS-based infectious disease testing has demonstrated analytical validity, interpretation challenges remain, including differentiation of pathogenic organisms from colonization or contamination, and uncertain impact on clinical decision-making in many outpatient settings. As a result, NGS is generally considered an adjunctive tool rather than a first-line diagnostic modality in infectious disease management.

GENETIC TESTING AND INTERPRETATION

Experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be difficult and complex. Specialists are available to assist individuals to understand the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods. Refer to the Genetic Testing and Counseling policy for more information.

Summary of Evidence

For each test addressed, a literature review was conducted. The literature review was not comprehensive, but sufficient to establish lack of clinical utility. If it is determined that enough evidence has accumulated to reevaluate its potential clinical utility, the test will be removed from this evidence review and addressed separately. The lack of demonstrated clinical utility of these tests is based on the following factors: (1) there is no or extremely limited published data addressing the test; and/or (2) there is insufficient evidence demonstrating the clinical validity of the test.

Diagnostic Testing

For individuals with symptoms of various conditions who receive diagnostic testing with a miscellaneous genetic, molecular test (e.g., DNA Methylation Pathway Profile, Celiac PLUS, GI Effects [Stool], IBD sgi Diagnostic, Know Error), or laboratory diagnostic test the evidence is limited. Relevant outcomes are overall survival (OS), disease-specific survival, test accuracy and validity, change in disease status, and morbid events. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Prognostic Testing

For individuals who are diagnosed with various conditions (e.g., Crohn's prognostic) there are no published studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, change in disease status, and morbid events. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Therapeutic Tests

Previously reviewed therapeutic tests are no longer commercially available; no commercially available therapeutic test is reviewed in this policy.

Miscellaneous Laboratory Tests

Individuals and providers need assurance that the tests they are utilizing lead to good health decisions and do not lead to patient harm. The risks of unverified miscellaneous laboratory testing include false-positive and false-negative results; which can lead to unnecessary treatment (with associated side effects), delay in or missed diagnosis and appropriate treatment(s). A useful laboratory test provides information to make a clinical management decision that improves the net health outcome.

There are a multitude of laboratory tests that lack clear evidence of safety and efficacy. Although the FDA approves and clears many types of laboratory tests for blood, saliva or tissue if they are used by many different hospitals and labs, for almost 50 years the FDA has given leeway to individual labs to develop and use their own tests in-house, as long as the labs meet certain standards.

Multiple factors can affect the accuracy/safety/efficacy of a laboratory test including:

- The test manufacturer
- What the test is used for and if it is known for being reliable
- A tests sensitivity and specificity to a specific disease
- Testing conditions, methods and equipment used to complete the test
- Storage and transportation of the blood samples
- Timing of the test in relation to the disease being evaluated
- Timing of food, beverages, and medications

For many years, the FDA has engaged in conversations regarding the oversight of laboratory testing. Concerns exist regarding the safety and efficacy of laboratory testing regarding prognostic, diagnostic, and therapeutic use. The FDA has maintained that these risks can be mitigated by ensuring the safety and effectiveness of these tests through oversight. On September 29, 2023, the FDA announced a proposed rule aimed at helping to ensure that in vitro diagnostic products (IVDs) are devices under the Federal Food, Drug, and Cosmetic Act including when the manufacturer of the IVD is a laboratory. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

Carbapenemase Enzyme Activity

For individuals with carbapenemase-producing organisms who receive phenotypic carbapenemase enzyme activity testing, the evidence includes laboratory-based evaluations of assays designed to detect functional carbapenemase production. These assays may identify carbapenemase activity in cultured isolates; however, evidence is insufficient to demonstrate

that test results improve clinical management, antimicrobial stewardship decisions, infection prevention outcomes, or patient-centered outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Carbapenemase Resistance-Gene Testing

For individuals with suspected or confirmed carbapenem-resistant gram-negative bacterial infections who receive carbapenemase resistance-gene testing, there are no published studies demonstrating that use of testing improves clinical outcomes. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, change in disease status, morbid events, hospitalization, and time to effective therapy. Molecular assays can detect specific carbapenemase resistance genes, such as *KPC*, *NDM*, *VIM*, *IMP*, and *OXA-48-like* genes; however, limitations include false-positive and false-negative results, reduced performance of some multiplex assays due to target competition, and the inability to determine whether detected genes are expressed as functional carbapenemase enzymes. In addition, not all carbapenem-resistant organisms harbor carbapenemase genes, and current standards for determining antimicrobial susceptibility continue to rely on culture-based and phenotypic susceptibility testing. Although available studies support the analytical validity of molecular assays for detecting carbapenemase resistance genes, evidence demonstrating that test-guided management improves patient-centered outcomes is lacking. The evidence is insufficient to determine that carbapenemase resistance-gene testing results in an improvement in the net health outcome.

Next-Generation Sequencing (NGS)

For individuals who receive next-generation sequencing-based infectious disease testing, including sequencing of conserved ribosomal RNA gene targets or plasma-based sequencing for fungal and acid-fast bacterial DNA, the evidence includes observational studies, narrative reviews, and expert consensus. NGS may detect a broader range of organisms than conventional methods, including organisms not identified by culture; however, the clinical significance of additional findings is uncertain, particularly when results may reflect colonization, contamination, or commensal organisms. Evidence demonstrating that NGS improves clinical management, time to effective therapy, or patient-centered outcomes is lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms. The following is a summary of the key literature to date.

DIAGNOSTIC TESTING

Clinical Context and Test Purpose

The policy includes both genetic/molecular testing and miscellaneous laboratory diagnostic testing. The following framework applies broadly to evaluation of diagnostic test performance and clinical utility. For genetic testing, a symptomatic individual is defined as an individual with a clinical phenotype that correlates with a known pathologic variant.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

No studies examining clinical utility were identified.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

It is not possible to construct a chain of evidence for clinical utility due to the lack of clinical validity.

Diagnostic Testing for Multiple Conditions: DNA Methylation Pathway Profile

No full-length, peer-reviewed studies of the DNA Methylation Pathway Profile were identified.

Section Summary: DNA Methylation Pathway Profile

No studies were identified that evaluated this test. Factors that support a chain of evidence for prognostic or diagnostic utility are lacking.

Diagnostic Testing for Multiple Conditions: Know Error Specimen Provenance Assay

Evidence for the clinical validity of the Know Error Specimen Provenance Assay is lacking. There is some evidence on the application of short tandem repeat testing for specimen provenance assays in general,(27) but these data are not specific to the Know Error test.

Section Summary: Know Error Specimen Provenance Assays

There is a lack of published evidence on the use of the Know Error test to confirm tissue of origin. Studies are needed that compare the use of Know Error with standard laboratory quality measures and that demonstrate a reduction in specimen provenance errors associated with the use of Know Error.

Diagnostic Testing for Celiac Disease: Celiac PLUS

Celiac PLUS tests for genetic and serologic factors known to be associated with celiac disease. All 7 test components are included in an evidence-based diagnostic algorithm developed by the American College of Gastroenterology.(28) However, algorithmic testing is individualized according to the baseline risk of disease and is done sequentially, rather than simultaneously as in Celiac PLUS.

No studies of the combined serologic and genetic Celiac PLUS test were identified. Information about clinical validity of obtaining several serologic and genetic tests at once (i.e., Celiac PLUS) is lacking; improved sensitivity and reduced specificity may be expected.

Section Summary: Celiac Disease

No studies examining the clinical utility of Celiac PLUS were identified. Factors that support a chain of evidence for prognostic or diagnostic utility are lacking.

Diagnostic Testing for Irritable Bowel Syndrome: GI Effects Comprehensive Stool Profile

No studies were identified that assessed the accuracy of the GI Effects fecal panel for diagnosing IBS or for documenting “gut health,” a concept that may be difficult to define given large interindividual variability in gut flora.(29)

Section Summary: Diagnostic Testing for Irritable Bowel Syndrome

Evidence for the clinical validity and utility of the GI Effects Comprehensive Stool Profile is lacking. Because probiotics are not currently a standard treatment of IBS, the impact of test results on disease management is uncertain; i.e., a chain of evidence for clinical utility of the test cannot be established.

Diagnostic Testing for Inflammatory Bowel Disease: IBD sgi Diagnostic

The IBD sgi Diagnostic product monograph includes an extensive bibliography that documents associations of the 18 component markers, individually and in combination, with ulcerative colitis (UC) and/or Crohn disease (CD).(30)

In a review of the monograph, Shirts et al (2012) (31) observed that serologic tests for ASCA-IgA, ASCA-IgG, and atypical perinuclear anti-neutrophil cytoplasmic antibody are standard of care in the diagnostic workup of IBD,(32,33) although not all investigators include these tests in recommended diagnostic strategies.(34-37) These 3 markers are included in the 17-marker panel. Based on a 2006 meta-analysis of 60 studies (total N=11,608), pooled sensitivity and specificity of the 3-test panel were 63% and 93%, respectively, for diagnosing IBD.(38) Because the product monograph does not compare the 18-marker panel with the 3-marker panel, incremental improvement in diagnosis with the 18-marker panel is unknown. Shirts et al (2012) calculated an area under the curve (AUC) for the 3-marker panel of 0.899.

Published evidence supports associations of each marker in the 18-marker panel, alone and in combination, with IBD diagnosis. Based on manufacturer data, the accuracy for IBD diagnosis of the 18-marker panel exceeds that of each component marker, but the relevant comparison—with a panel of 3 markers that has good discrimination for IBD—was not included; subsequent analysis suggests that the panels may perform similarly. Performance characteristics for the 18-marker panel to distinguish ulcerative colitis from CD were not provided.

Section Summary: Inflammatory Bowel Disease sgi Diagnostic

No studies examining the clinical utility of IBD sgi Diagnostic were identified. Although manufacturer data support clinical validity of the test for diagnosing IBD, this evidence is insufficient to support a chain of evidence for clinical utility due to lack of details about study methodology and lack of replication of the findings. For distinguishing ulcerative colitis from CD, clinical validity has not been established; therefore, a chain of evidence for clinical utility for this purpose cannot be established.

Diagnostic Testing to Identify Interstitial Pneumonia Patterns: Envisia

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. There is insufficient evidence in the peer reviewed medical literature regarding how the use of genomic testing would change patient management or improve health outcomes. Current evidence is insufficient to demonstrate that use of genomic classifier testing improves net health outcomes, and major society guidelines do not recommend routine use as standard diagnostic practice to complement high-resolution chest CT to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases in patients who do not have a definite usual interstitial pneumonia. Unbiased, large, prospective, multicenter studies are needed to determine the clinical utility.

CARBAPENEMASE ENZYME ACTIVITY TESTING

Clinical Context and Test Purpose

Diagnostic Testing for Carbapenemase Enzyme Activity

Carbapenemase enzyme activity testing is intended to identify carbapenemase-producing organisms among gram-negative bacterial isolates. Carbapenemases are enzymes that hydrolyze carbapenem antibiotics and contribute to antimicrobial resistance. Phenotypic testing methods evaluate the functional ability of an organism to inactivate a carbapenem antibiotic and may assist in infection prevention activities and antimicrobial stewardship efforts.

Clinically Valid

A test must accurately identify the presence or absence of carbapenemase enzyme activity. Phenotypic methods such as the modified carbapenem inactivation method (mCIM), Carba NP testing, and other carbapenem hydrolysis assays have demonstrated the ability to detect carbapenemase-producing organisms in microbiology laboratory settings. These assays assess enzymatic activity rather than specific resistance genes and may be used to characterize carbapenem-resistant bacterial isolates. However, published evidence evaluating the impact of these tests on patient-centered clinical outcomes remains limited. Reference standards vary across studies and the clinical significance of test results beyond standard microbiology workflows has not been clearly established.(46-49)

Clinically Useful

A test is clinically useful if use of the test results informs management decisions that improve the net health outcome of care.

Direct Evidence

Direct evidence of clinical utility is provided by studies comparing health outcomes in patients managed with and without the test.

No studies were identified demonstrating that use of carbapenemase enzyme activity testing improves health outcomes, reduces mortality, shortens hospitalization, decreases time to effective therapy, or improves other patient-centered outcomes when compared with conventional microbiology testing strategies.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity and evidence that test results lead to improved management decisions and improved health outcomes.

Although phenotypic carbapenemase assays can identify functional carbapenemase activity, evidence is insufficient to demonstrate that the use of these assays results in changes in clinical management that improve net health outcomes. Studies evaluating downstream effects on treatment outcomes, infection control outcomes, or antimicrobial stewardship interventions are limited.

Section Summary: Carbapenemase Enzyme Activity Testing

Carbapenemase enzyme activity testing uses phenotypic methods, including the modified carbapenem inactivation method (mCIM) and Carba NP testing, to detect functional carbapenemase production in bacterial isolates. Although these assays demonstrate analytical capability to identify carbapenemase-producing organisms, evidence demonstrating clinical utility is lacking. Published literature has not established that the use of carbapenemase enzyme activity testing results in improved patient outcomes or improved net health outcomes. Therefore, the evidence is insufficient to support clinical utility.

CARBAPENEMASE RESISTANCE-GENE TESTING

Clinical Context and Test Purpose

Diagnostic Testing for Carbapenemase Resistance Genes

Carbapenemase resistance-gene testing is intended to identify genetic determinants associated with carbapenemase production among gram-negative bacterial isolates. Molecular assays detect specific resistance genes, such as *KPC*, *NDM*, *VIM*, *IMP*, and *OXA-48-like* genes, that encode carbapenemase enzymes responsible for carbapenem antibiotic resistance. These tests may be used to characterize carbapenem-resistant organisms and can provide information regarding the genetic mechanism of resistance.

Clinically Valid

A test must accurately identify the presence or absence of carbapenemase resistance-genes. Molecular assays have demonstrated the ability to detect specific carbapenemase resistance-genes in bacterial isolates.

Clinically Useful

A test is clinically useful if use of the test results informs management decisions that improve the net health outcome of care.

Direct Evidence

Direct evidence of clinical utility is provided by studies comparing health outcomes in patients managed with and without the test.

No studies were identified demonstrating that use of carbapenemase resistance-gene testing improves health outcomes, reduces mortality, shortens hospitalization, decreases time to effective therapy, or improves other patient-centered outcomes when compared with conventional microbiology testing strategies. Current standards for determining antimicrobial susceptibility continue to rely on bacterial culture and phenotypic susceptibility testing to identify effective antibiotic treatment options.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity and evidence that test results lead to improved management decisions and improved health outcomes.

Review of Evidence

Polymerase chain reaction (PCR)-based and multiplex molecular platforms can rapidly identify common carbapenemase genes, including *KPC*, *NDM*, *VIM*, *IMP*, and *OXA-48-like* variants. However, limitations have been reported. Reinicke et al (2025) and Chamizo-Lopez et al (2025) noted that assays evaluating multiple resistance targets simultaneously may experience reduced performance due to target competition, potentially affecting detection accuracy. In addition, false-positive and false-negative results may occur. Detection of a resistance-gene does not necessarily confirm expression of a functional carbapenemase enzyme, and not all carbapenem-resistant organisms harbor carbapenemase genes. As a result, molecular findings may not fully characterize the resistance phenotype of an organism. The American Society for Microbiology (2026) points out that not all organisms that are resistant to carbapenems actually express carbapenemases. The National Institute of Allergy and Infectious Diseases (2020) indicates the standard of care to determine antibiotic resistance involves a culture of the bacteria and testing to see which types of antibiotics work against that particular strain.

Section Summary: Carbapenemase Resistance Gene Testing

Carbapenemase resistance gene testing uses molecular methods to detect specific genetic determinants associated with carbapenemase production. Although these assays can rapidly identify resistance genes, limitations include incomplete correlation between genotype and phenotype, inability to confirm expression of functional carbapenemase enzymes, and restricted detection to targeted genes. Available evidence primarily addresses analytical performance, while evidence demonstrating improvements in clinical decision making, antimicrobial stewardship outcomes, infection prevention measures, or patient-centered outcomes remains limited. Therefore, the evidence is insufficient to establish the clinical utility of carbapenemase resistance gene testing.

PROGNOSTIC TESTING

Clinical Context and Test Purpose

The purpose of prognostic testing of diagnosed disease is to predict natural disease course (e.g., aggressiveness, risk of recurrence, death). This type of testing uses gene expression of affected tissue to predict the course of disease.

Prognostic Testing for Crohn Disease with Crohn's Prognostic

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

No studies of the 6-marker Crohn's Prognostic test were identified.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

Direct evidence for clinical utility is lacking.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

It is not possible to construct a chain of evidence for clinical utility due to the lack of clinical validity.

Section Summary: Crohn's Prognostic

Direct and indirect evidence for clinical utility of the Crohn's Prognostic test to identify individuals likely to have an aggressive disease course are currently lacking.

NEXT-GENERATION SEQUENCING (NGS)

Next-generation sequencing (NGS) is a high-throughput molecular technology that enables the simultaneous sequencing of millions of DNA or RNA fragments, allowing comprehensive, unbiased analysis of all genetic material within a clinical specimen. In infectious diseases, NGS is proposed as a diagnostic tool to identify a broad range of pathogens—including bacteria, viruses, fungi, and parasites—from a single sample without requiring prior knowledge of the suspected organism, with particular utility in detecting rare, fastidious, or unculturable organisms and in identifying polymicrobial infections or antimicrobial resistance genes. These capabilities may improve diagnostic yield, especially in complex or culture-negative cases. However, significant limitations exist, including difficulty distinguishing true infection from colonization or contamination, variability in test performance and lack of standardization, complex data interpretation requiring specialized bioinformatics, higher cost and longer turnaround times compared to conventional methods, and limited evidence demonstrating that its use improves clinical outcomes. As a result, NGS is generally considered an adjunctive tool rather than a first-line diagnostic modality in infectious disease management.

An expert consensus by Lefterova et al (2015) evaluated the use of next-generation sequencing (NGS) for infectious disease diagnosis and management. NGS allows for broad,

culture-independent detection of pathogens and identification of antimicrobial resistance markers. The report highlights its potential to detect rare, novel, and polymicrobial infections. However, significant limitations are noted, including lack of assay standardization, risk of contamination, complex data interpretation, and limited evidence demonstrating clinical utility. The authors conclude that additional validation and outcome-based studies are necessary before widespread clinical adoption.

Ishihara et al (2020) conducted an observational comparative study (n=50) comparing NGS with conventional urine culture for the diagnosis of urinary tract infections. NGS identified a greater number and diversity of bacterial species, including organisms not detected by culture, particularly in polymicrobial infections. However, NGS also detected commensal and potentially nonpathogenic organisms, limiting specificity. Outcomes demonstrated improved detection rates but no clear evidence that this translated into improved clinical decision-making or patient outcomes.

Choi et al (2021) evaluated NGS for pathogen identification compared to standard culture methods in infected foot ulcers in an observational cohort study (n=51). NGS identified a broader range of organisms, including anaerobic and fastidious bacteria not captured by culture. Despite increased pathogen detection, there was no consistent evidence that NGS findings significantly altered treatment decisions or improved healing outcomes. The study highlights uncertainty regarding the clinical significance of additional organisms identified by NGS.

In a narrative review, Rodino et al (2024) summarized the current status of NGS in infectious disease diagnostics. NGS offers comprehensive, hypothesis-free pathogen detection and may be useful in complex or atypical infections. However, challenges persist, including variability in testing methods, high cost, limited standardization, and uncertain clinical impact. The review emphasizes that evidence demonstrating improved patient outcomes is insufficient, and NGS is best considered an adjunctive tool pending further clinical validation.

Hulick (2024; UpToDate) described the principles and clinical applications of NGS across multiple domains, including infectious disease. NGS enables high-throughput sequencing for broad pathogen detection, particularly in cases where conventional diagnostic methods are inconclusive. While NGS has demonstrated increased diagnostic yield in select scenarios, its clinical role remains adjunctive due to limitations such as cost, turnaround time, and challenges distinguishing colonization from true infection. Evidence supporting improved patient outcomes compared to standard testing remains limited.

Section Summary: Next-Generation Sequencing

Next-generation sequencing (NGS) is a high-throughput technology that enables comprehensive detection of a wide range of pathogens from a single sample without requiring prior target identification. Evidence indicates that NGS can increase pathogen detection, particularly in complex or difficult-to-diagnose cases. However, this increased sensitivity is accompanied by notable limitations, including challenges in distinguishing clinically relevant findings from background organisms, variability in test performance, lack of standardization, complex interpretation, and higher costs and turnaround times compared to conventional methods. Importantly, current evidence has not consistently demonstrated that use of NGS improves clinical decision-making or patient outcomes. Overall, NGS is best considered an

adjunctive diagnostic tool with potential value in select scenarios, but insufficient evidence supports its routine use as a first-line approach in infectious disease diagnosis.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

A search of ClinicalTrials.gov did not identify any ongoing or unpublished trials that might influence this review.

Supplemental Information

PRACTICE GUIDELINES AND POSITION STATEMENTS

American College of Gastroenterology

Celiac Disease

The American College of Gastroenterology (2023) published a clinical practice update for the diagnosis and management of celiac disease.(39) A recommendation for genetic testing using a multigene panel test (e.g., Celiac PLUS) was not included.

Inflammatory Bowel Disease

The American College of Gastroenterology (2018) practice guidelines on Crohn disease (40) states that genetic and routine serologic testing is not indicated to establish the diagnosis of Crohn's disease.

Regulatory Status

Clinical laboratories may develop and validate laboratory-developed tests (LDTs) and offer them as laboratory services under the requirements of the Clinical Laboratory Improvement Amendments (CLIA). Historically, the FDA generally exercised enforcement discretion for most LDTs, allowing many tests to be marketed without FDA premarket review, clearance, or approval. CMS oversees laboratory operations and quality standards through CLIA requirements.

In May 2024, the FDA issued a final rule amending its regulations to clarify that in vitro diagnostic products (IVDs) are medical devices under the Federal Food, Drug, and Cosmetic Act, including when manufactured by a laboratory, and established a phased approach to increase FDA oversight of LDTs. However, in March 2025, a federal district court vacated the 2024 final rule. Subsequently, in September 2025, the FDA formally reverted the regulatory language to its prior framework. As a result, LDTs continue to operate primarily under CLIA requirements, although the regulatory oversight of LDTs remains an evolving area of federal policy. The FDA, CMS, and Congress continue to evaluate appropriate approaches to the regulation of laboratory-developed testing.

Government Regulations

National:

There is no national determination on this topic.

Local:

MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test (L37919);
Original Effective Date: 5/13/19; Revision Effective Date: 6/29/23

This policy provides limited coverage for the Envisia™ Genomic Classifier (Veracyte™, Inc., South San Francisco, CA), a tissue based multi-analyte assay with algorithm analysis test (hereafter called Envisia) for interstitial lung disease (ILD) patients who are suspected of having idiopathic pulmonary fibrosis (IPF) and who do not have a definitive usual interstitial pneumonia (UIP) pattern by high resolution computed tomography (HRCT) or other known cause of ILD. IPF suspicion increases significantly in patients greater than 60 years of age when HRCT is not definitive, and comorbidities in this population make clinicians reluctant to perform surgical lung biopsy to obtain a diagnosis due to significant procedure morbidity and mortality. Envisia™ testing is performed on less-invasive bronchoscopy transbronchial biopsy (TBB) samples and is intended to provide a categorical UIP or non-UIP result that along with clinical and radiographic information may guide treatment without the need or risk of surgical lung biopsy.

Billing and Coding: MoIDX: know error®. A55172. Original Effective Date 02/16/2017; Revision Effective Date 01/01/2023. Retired 5/30/24

The know error® DNA Specimen Provenance Assay is a forensic assay to confirm that a surgical specimen belongs to the patient evaluated for treatment. Although MoIDX agrees that the healthcare community should define and follow strict procedures regarding patient and patient specimen identification and handling, tests performed to measure the quality of a process do not provide information to diagnose or treat a patient illness or injury as defined in the Medicare benefit category. Therefore, the know error® DNA Specimen Provenance Assay is a statutorily excluded test. Although an Advance Beneficiary Notice (ABN) is not required for a statutory exclusion, providers supplying this test (directly or through a purchased service) should ensure patients understand the test is not a covered benefit.

To receive a DNA Specimen Provenance Assay service denial, please submit the following claim information:

- CPT code 84999 – unlisted chemistry procedure

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicaid Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
- BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
- Cardiovascular Risk Panels
- Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)

- Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
- CPT Category III Codes-Noncovered Services
- Evaluation of Biomarkers for Alzheimer's Disease
- Gene Analysis for Corneal Dystrophy
- Gene Expression Profile Analysis for Risk Stratification for Prostate Cancer Management
- Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer (e.g., ColoPrint, Conon PRS, GeneFx, OncoDefender, Oncotype Dx Colon Cancer Test)
- Gene Expression Profiling for Cutaneous Melanoma
- Gene Expression Profiling for Uveal Melanoma
- Genetic and Laboratory Testing for Use of 5-Fluorouracil in Patients with Cancer
- Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
- Genetic Testing - Analysis of MGMT Promoter Methylation in Malignant Gliomas
- Genetic Testing - Assays of Genetic Expression in Tumor Tissue as a Technique to Help Guide Decision-Making in Patients With Breast Cancer
- Genetic Testing - *BRAF* Mutation in Selecting Melanoma Patients for Targeted Therapy
- Genetic Testing - Carrier Screening for Genetic Diseases
- Genetic Testing - Chromosomal Microarray (CMA) Analysis and Next-Generation Sequencing Panels, for the Evaluation of Children with Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and/or Congenital Anomalies
- Genetic Testing - Chromosomal Microarray Testing for the Evaluation of Early Pregnancy Loss and Intrauterine Fetal Demise
- Genetic Testing - Fetal RHD Genotyping Using Maternal Plasma
- Genetic Testing - Human Leukocyte Antigen Testing for Celiac Disease
- Genetic Testing - Human Platelet Antigen Genotyping
- Genetic Testing - *JAK2*, *MPL* and *CALR* Testing for Myeloproliferative Neoplasms
- Genetic Testing - Microarray Testing for Cancers of Unknown Primary (CUP) Origin
- Genetic Testing - Molecular Markers in Fine Needle Aspirates (FNA) of the Thyroid
- Genetic Testing - Molecular Testing for the Diagnosis and Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreaticobiliary Lesions (e.g., PathFinderTG®, PancraGEN, BarreGEN)
- Genetic Testing - NGS of Multiple Genes (Panel) for Malignant Conditions
- Genetic Testing - Noninvasive Prenatal Screening For Fetal Aneuploidies, Microdeletions, Single-Gene Disorders, and Twin Zygosity Using Cell-Free Fetal DNA
- Genetic Testing - Preimplantation
- Genetic Testing - Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Non-Small-Cell Lung Cancer (*EGFR*, *ALK*, *BRAF*, *ROS1*, *RET*, *MET*, *KRAS*, *HER2*, *PD-L1*, *TMB*)
- Genetic Testing - Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
- Genetic Testing and Counseling
- Genetic Testing for Alpha1-Antitrypsin Deficiency
- Genetic Testing for Alzheimer's Disease
- Genetic Testing for Amyotrophic Lateral Sclerosis
- Genetic Testing for Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D)
- Genetic Testing for Bloom Syndrome

- Genetic Testing for Cardiac Ion Channelopathies (e.g., Congenital Long QT Syndrome, Brugada Syndrome, etc.)
- Genetic Testing for Cystic Fibrosis
- Genetic Testing for Cytochrome P450 Polymorphisms
- Genetic Testing for Dilated Cardiomyopathy
- Genetic Testing for Duchenne and Becker Muscular Dystrophy
- Genetic Testing for Epilepsy
- Genetic Testing for Familial Cutaneous Malignant Melanoma (*CDKN2A*)
- Genetic Testing for *FLT3*, *NPM1*, *CEBPA*, *IDH1* and *IDH2* Variants in Acute Myeloid Leukemia
- Genetic Testing for *FMR1* and *FMR2* Variants (Including Fragile X and Fragile XE Syndromes)
- Genetic Testing for Hereditary Hearing Loss
- Genetic Testing for Hereditary Hemochromatosis
- Genetic Testing for Heterozygous Familial Hypercholesterolemia
- Genetic Testing for Huntington Disease
- Genetic Testing for Inherited Hypertrophic Cardiomyopathy
- Genetic Testing for Inherited Thrombophilias
- Genetic Testing for *KRAS*, *NRAS*, and *BRAF* Mutation Analysis in Metastatic Colorectal Cancer
- Genetic Testing for Li-Fraumeni Syndrome
- Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
- Genetic Testing for Macular Degeneration
- Genetic Testing for Marfan Syndrome, Ehlers-Danlos, Thoracic Aortic Aneurysms and Dissections, and Connective Tissue Related Disorders
- Genetic Testing for Mitochondrial Disorders
- Genetic Testing for Myotonic Dystrophy
- Genetic Testing for Noonan Spectrum Disorder
- Genetic Testing for Pharmacogenetic Pain Management
- Genetic Testing for Prader-Willi and Angelman Syndromes (Chromosome 15 Abnormalities)
- Genetic Testing for PTEN Hamartoma Tumor Syndrome
- Genetic Testing for Retinal Dystrophies
- Genetic Testing for Rett Syndrome
- Genetic Testing for Specified Conditions Using Testing Panels
- Genetic Testing for Statin-Induced Myopathy
- Genetic Testing for Tay-Sachs Disease
- Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies
- Genetic Testing of CADASIL Syndrome
- Genetic Testing (Single Nucleotide Variants) to Predict Risk of Nonfamilial Breast Cancer
- Genotype-Guided Warfarin Dosing
- Germline Genetic Testing for *BRCA1*, *BRCA2*, and *PALB2* for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
- Germline Genetic Testing for Gene Variants Associated with Breast Cancer in Individuals at Moderate and High Breast Cancer Risk (e.g., *CHEK2*, *ATM*, *BARD1*, etc.)
- Identification of Microorganisms Using Nucleic Acid Probes
- Laboratory Tests Post Transplant (Kidney and Heart) and for Heart Failure

- Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) and Secretory Type II Phospholipase A2 (sPLA2-IIA) in the Assessment of Cardiovascular Risk
- Molecular Testing in the Management of Pulmonary Nodules
- Multimarker Serum Testing Related to Ovarian Cancer (e.g., OVA1®, Overa™, OvaWatch and ROMA™ testing)
- Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
- Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines
- Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer (NSCLC), e.g., VeriStrat®
- Serological Genetic and Molecular Screening for Colorectal Cancer
- Serum Biomarker Human Epididymis Protein 4 (*HE4*)
- Serum Markers for the Diagnosis of Inflammatory Bowel Disease
- Somatic Biomarker Testing (including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Metastatic Colorectal Cancer (*KRAS, NRAS, BRAF, MMR/MSI, HER2, and TMB*)
- Urinary Biomarkers for Bladder Cancer

References

1. Pfeifer JD, Zehnbaauer B, Payton J. The changing spectrum of DNA-based specimen provenance testing in surgical pathology. *Am J Clin Pathol.* Jan 2011;135(1):132-138. PMID 21173135
2. Beauvais W, Fournie G, Jones BA, et al. Modelling the expected rate of laboratory biosafety breakdowns involving rinderpest virus in the post-eradication era. *Prev Vet Med.* Nov 1, 2013;112(3-4):248-256. PMID 24029703
3. Pallav K, Kabbani T, Tariq S, et al. Clinical utility of celiac disease-associated HLA testing. *Dig Dis Sci.* Sep 2014;59(9):2199-2206. PMID 24705698
4. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. *Gut.* Jan 2013;62(1):43-52. PMID 22345659
5. Prometheus® Therapeutics and Diagnostics. IBD sgi Diagnostic <https://prometheuslabs.com/disease-tests/ibd-sgi-diagnostic/#>. Accessed December 29, 2025.
6. Pietzak MM, Schofield TC, McGinniss MJ, et al. Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles. *Clin Gastroenterol Hepatol.* Sep 2009;7(9):966-971. PMID 19500688
7. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. *Am J Gastroenterol.* Oct 2014;109(10):1547-1561; quiz 1546, 1562. PMID 25070051
8. National Institute for Health and Care Excellence (NICE). Irritable bowel syndrome in adults: diagnosis and management [CG61]. 2017; <https://www.nice.org.uk/guidance/cg61>. Accessed December 29, 2025.
9. McKenzie YA, Alder A, Anderson W, et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. *J Hum Nutr Diet.* Jun 2012;25(3):260-274. PMID 22489905

10. Weinberg DS, Smalley W, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome. *Gastroenterology*. Nov 2014;147(5):1146-1148. PMID 25224526
11. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. Aug 2014;11(8):506-514. PMID 24912386
12. Trinkley KE, Nahata MC. Treatment of irritable bowel syndrome. *J Clin Pharm Ther*. Jun 2011;36(3):275-282. PMID 21545610
13. Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. *Aliment Pharmacol Ther*. Oct 2013;38(8):864-886. PMID 23981066
14. Ortiz-Lucas M, Tobias A, Saz P, et al. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. *Rev Esp Enferm Dig*. Jan 2013;105(1):19-36. PMID 23548007
15. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. *Curr Opin Clin Nutr Metab Care*. Nov 2011;14(6):581-587. PMID 21892075
16. Stevenson C, Blaauw R, Fredericks E, et al. Randomized clinical trial: effect of *Lactobacillus plantarum* 299 v on symptoms of irritable bowel syndrome. *Nutrition*. Oct 2014;30(10):1151-1157. PMID 25194614
17. Shavakhi A, Minakari M, Farzamnia S, et al. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. *Adv Biomed Res*. 2014;3:140. PMID 25161987
18. Ludidi S, Jonkers DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. *Neurogastroenterol Motil*. May 2014;26(5):705-714. PMID 24588932
19. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing *Bacillus Coagulans* in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. *Gastroenterol Hepatol Bed Bench*. Summer 2014;7(3):156-163. PMID 25120896
20. Urgesi R, Casale C, Pistelli R, et al. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and *Bacillus coagulans* (Colinox(R)) in patients with irritable bowel syndrome. *Eur Rev Med Pharmacol Sci*. 2014;18(9):1344-1353. PMID 24867512
21. Sisson G, Ayis S, Sherwood RA, et al. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12-week double-blind study. *Aliment Pharmacol Ther*. Jul 2014;40(1):51-62. PMID 24815298
22. Genova Diagnostics. GI Effects® Comprehensive Profile – Stool; n.d.; <https://www.gdx.net/product/gi-effects-comprehensive-stool-test>. Accessed December 29, 2025.
23. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. *Gastroenterology*. Jun 2005;128(7):2020-2028. PMID 15940634
24. Ippoliti A, Devlin S, Mei L, et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. *Inflamm Bowel Dis*. Aug 2010;16(8):1279-1285. PMID 20027650
25. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. *Gastroenterology*. Sep 2002;123(3):679-688. PMID 12198692

26. Genova Diagnostics. ImmunoGenomic® Profile; n.d.; <https://www.gdx.net/product/immunogenomic-profile-saliva>. Accessed November 21, 2024. No longer populates December 29, 2025.
27. Pfeifer JD, Singleton MN, Gregory MH, et al. Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens. *Value Health*. Sep-Oct 2012;15(6):860-867. PMID 22999136
28. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol*. May 2013;108(5):656-676; quiz 677. PMID 23609613
29. Hanaway P. Ask the experts. *Explore (NY)*. May 2006;2(3):284. PMID 16781657
30. Prometheus Therapeutics & Diagnostics. IBD sgi Diagnostic. <https://www.prometheusbiosciences.com/ibd-sgi/>. Accessed November 21, 2024. No longer populates December 29, 2025.
31. Shirts B, von Roon AC, Tebo AE. The entire predictive value of the prometheus IBD sgi diagnostic product may be due to the three least expensive and most available components. *Am J Gastroenterol*. Nov 2012;107(11):1760-1761. PMID 23160303
32. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. *Autoimmun Rev*. Apr-May 2014;13(4-5):463-466. PMID 24424198
33. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn's disease. *Autoimmun Rev*. Apr-May 2014;13(4-5):467-471. PMID 24424189
34. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. *Lancet*. Nov 3, 2012;380(9853):1606-1619. PMID 22914296
35. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. Mar 2010;105(3):501-523; quiz 524. PMID 20068560
36. Baumgart DC, Sandborn WJ. Crohn's disease. *Lancet*. Nov 3, 2012;380(9853):1590-1605. PMID 22914295
37. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. *Am J Gastroenterol*. Feb 2009;104(2):465-483; quiz 464, 484. PMID 19174807
38. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. *Am J Gastroenterol*. Oct 2006;101(10):2410-2422. PMID 16952282
39. Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Lebwohl B. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. *Am J Gastroenterol*. 2023;118(1):59-76. doi:10.14309/ajg.0000000000002075.
40. Lichtenstein, GG, Loftus, EE, Isaacs, KK, Regueiro, MM, Gerson, LL, Sands, BB. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am. J. Gastroenterol.*, 2018 Apr 4;113(4). PMID 29610508.
41. Veracyte. Interstitial lung diseases – Envisia Genomic Classifier. 2021.21 https://lung.veracyte.com/envisia/?gclid=Cj0KCQiAo7KqBhDhARIsAKhZ4uh0Vzch88xxzFDep_AqbWq7Y6ExebfngkyhPr9m6oXVt8jLEm9CRWlaAlwwEALw_wcB&gclidsrc=aw.ds. Accessed November 21, 2024. Information no longer populates. December 29, 2025.
42. Choi Y, Liu TT, Pankratz DG, et al. Identification of usual interstitial pneumonia pattern using RNA-Seq and machine learning: challenges and solutions. *BMC Genomics*. 2018;19(Suppl 2):101.
43. Choi Y, Lu J, Hu Z, et al. Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia. *BMC Pulm Med*. 2017;17(1):141.

44. Richeldi L, Scholand MB, et al. Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. *Am J Respir Crit Care Med*. 2021 Jan 15;203(2):211-220. doi: 10.1164/rccm.202003-0877OC. PMID: 32721166.
45. Centers for Medicare & Medicaid Services. MoIDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test (L37919). <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37919&ver=12&keyword=envisia&keywordType=starts&areald=s27&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>. Accessed December 29, 2025.
46. U.S. Food and Drug Administration. Laboratory Developed Tests. Updated September 19, 2025. <https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests>. Accessed July 23, 2026.
47. U.S. Food and Drug Administration. Medical Devices; Laboratory Developed Tests; Final Rule. *Federal Register*. 2024;89(88):37286-37536. Published May 6, 2024.
48. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100. 35th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2025.
49. Centers for Disease Control and Prevention (CDC). Antimicrobial Resistance and Patient Safety Portal: Carbapenem-resistant Enterobacterales (CRE) and Carbapenemase-producing Organisms. U.S. Department of Health and Human Services; 2025. Available at: <https://arpsp.cdc.gov>. Accessed July 23, 2026.
50. Centers for Medicare & Medicaid Services. "Billing and Coding: MoIDX: know error." (A55172). 2023. RETIRED. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55172&ver=14&keywordtype=starts&keyword=know%20error&bc=0>. Accessed November 21, 2024.
51. Lefterova Martina I., Suarez Carlos J., Banaei Niaz, and Pinsky Benjamin A. Next-generation sequencing for infectious disease diagnosis and management: a report of the Association for Molecular Pathology. *The Journal of Molecular Diagnostics*. Vol 17, No. 6, November 2015.
52. Ishihara T, Watanabe N, Inoue S, et al. Usefulness of next-generation DNA sequencing for the diagnosis of urinary tract infection. *Drug Discov Ther*. 2020 Mar 8;14(1):42-49. doi: 10.5582/ddt.2020.01000. Epub 2020 Feb 27. PMID: 32101813.
53. Choi Y, Oda E, Waldman O, et al. Next-Generation Sequencing for Pathogen Identification in Infected Foot Ulcers. *Foot Ankle Orthop*. 2021 Jul 12;6(3):24730114211026933. doi: 10.1177/24730114211026933. PMID: 35097461.
54. Rodino KG, Simner PJ. Status check: next-generation sequencing for infectious-disease diagnostics. *J Clin Invest*. 2024 Feb 15;134(4):e178003. doi: 10.1172/JCI178003. PMID: 38357923.
55. Hulick, PJ. Next-generation DNA sequencing (NGS): principles and clinical applications. Updated 2026. <https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications>. Accessed June 11, 2026.
56. Reinicke M, Diezel C, Teimoori S, et al. "Rapid Simultaneous Detection of the Clinically Relevant Carbapenemase Resistance Genes blaKPC, blaOXA48, blaVIM and blaNDM with the Newly Developed Ready-to-Use qPCR CarbaScan LyoBead". *Int J Mol Sci*. 2025 Jan 30;26(3):1218. doi: 10.3390/ijms26031218. PMID: 39940986.
57. Chamizo-Lopez, FJ., Gutierrez-Fernandez, J., Rojo-Martin MD., et al. "Development and Validation of a Multiplex Real-Time PCR Assay for Rapid Screening of Main Carbapenemase Genes in Clinical Isolates and Surveillance Samples." *Antibiotics*. 2025 Apr 1;14(4):363. PMID: 40298527.

58. Smith, KP. Opening the Black Box of Phenotypic Carbapenemase Detection. Amer Soc for Microbio. 2026. <https://asm.org/articles/2019/may/opening-the-black-box-phenotypic-carbapenemase-det>. Accessed January 12, 2026.
59. Centers for Disease Control and Prevention. "Antimicrobial Resistance & Patient Safety Portal: Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CRPA) carrying multiple targeted carbapenemase genes." 2022. <https://arpsp.cdc.gov/profile/multi-mechanism/2021>. Accessed 6/10/26.
60. National Institute of Allergy and Infectious Diseases. Diagnosis, Antimicrobial (Drug) Resistance. 2020. <https://www.niaid.nih.gov/research/antimicrobial-resistance-diagnosis#:~:text=The%20process%20for%20diagnosing%20antibiotic%20resistance%20involves:,needed%20to%20avoid%20delays%20in%20appropriate%20treatment>. Accessed January 13, 2026.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 1/13/26, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
7/1/18	4/17/18	4/17/18	Joint policy established
3/1/19	12/11/18		• Routine maintenance • Removed Decision Dx Melanoma from policy; added related policy Gene Expression Profiling for Cutaneous Melanoma
3/1/20	12/17/19		• Routine maintenance
3/1/21	12/15/20		• Removed – no longer marketed ○ TransPredict Fc Gamma 3A ○ DecisionDX-Thymoma • FirstSight added (new proprietary lab - liquid bx for CRC)
3/1/22	12/14/21		• Routine maintenance • (Envisia) 81554 added as EI • LCD added for Envisia
5/1/22	2/15/22		• FirstSight, <i>SEPT9</i> (i.e., epi proColon) and Gene expression profiling (i.e., ColonSentry, Bescreened) for colon cancer screening transferred to “Serological Genetic and Molecular Screening for Colorectal Cancer” • Title changed from: Miscellaneous Genetic and Molecular Diagnostic Tests
5/1/23	2/21/23		• Routine maintenance (slp) • Vendor Managed: N/A
5/1/24	2/20/24		• Routine maintenance (slp) • Vendor Managed: N/A • BCBSA archived 2.04.121 - Incorporated the information into 2.04.159 with additions of PLA codes • ImmunoGenomic Profile and ResponseDX: Colon removed – no longer marketed

			• MPS updated – ○ therapeutic tests are no longer marketed ○ Addition of MPS statement r/t Misc testing
7/1/24	4/16/24		• Off cycle review • Codes added as EI – 81265, 81266 (Know Error testing) • LCA added for Know Error
5/1/25	2/18/25		• Routine maintenance (slp) • Vendor Managed: N/A
5/1/26	2/17/26		• Routine maintenance (slp) • Vendor Managed: N/A • Policy formatting updated • Carbapenem resistance testing (87182, 87183) added as EI
11/1/26	8/18/26		• Off cycle review • IMP added: NGS for Infectious Disease ○ Codes (EI): 0112U, 0531U

Next Review Date: 1st Qtr, 2027

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: MISCELLANEOUS AND GENETIC AND MOLECULAR DIAGNOSTIC TESTS

Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not Covered
BCNA (Medicare Advantage)	Refer to the Medicare information under the Government Regulations section of this policy.
BCN65 (Medicare Complementary)	Coinurance covered if primary Medicare covers the service.